Latest Conference Articles

Dr. Kaiser discusses how risuteganib fared in a phase II trial in patients with intermediate nonexudative AMD. 

ICYMI: Dr. Blinder compares the efficiencies between two surgical cutters

Eyes with persistent subretinal fluid fared better with visual acuity than eyes that were dry, according to the HARBOR Trial

ICYMI: Abicipar Phase II MAPLE Trial supports improved safety for patients with nAMD following a Modified Manufacturing Process

Glaucoma genetics research can define the molecular basis of glaucoma and targets for developing curative or even preventive therapies, and it also pro-vides a basis for diagnostic and screening tests.

While MIGS has forever changed the surgical management of glaucoma, the space continues to evolve.

This year’s ASRS PAT survey show subtle regional differences

 The ASRS Global Trends Survey finds differences in some treatment preferences

ICYMI: Dr. Packer shares the pearls from his 2019 ASCRS presentation 

ICYMI: ASRS-developed program aims to support physicians with confidential comparisons

Ever wondered what it's like to compete in a Shark Tank-like competition? Find out!

Optical coherence tomography angiography can detect microcirculatory disturbances during acute attacks.

Defining medicine and terms used can help move science forward

Researchers seeking fluid features, retinal integrity measures to test next step in image analysis and image interrogation in clinical trials.

David S. Boyer, MD, notes that the goal is to dry every patient out, with undertreatment the leading cause of a loss of visual acuity.

Researchers find that targeted subretinal delivery of stem cell derived RPE to geographic atrophy is feasible 

Annual meeting schedule to include presentations, live surgery, awards

Beyond the sessions, this year’s conference offers multiple events for attendees.

ICYMI: Frank W. Bowden, III, MD, FACS shares the take-home message from his 2019 ASCRS presentation. Check it out below!

Eva Liang, MD, discusses the take-home message from her presentation at ASCRS 2019

ICMYI: Dr. Tyson shares his pearls using the dexamethasone 0.4 mg insert (Dextenza, Ocular Therapeutix).

ICYMI: Dr. Shultz shares the results from a study comparing dual linear venturi phacoemulsification with adaptive fluidics systems using femtosecond-assisted grid pattern versus traditional phaco with horizontal chop

Robert Maloney, MD, shares how a novel system can assist refractive surgeons

Bausch + Lomb provides a company update at the 2019 ASCRS meeting. 

Here's why John Sheppard, MD, believes nutrition should be the cornerstone of dry eye therapy.